摘要
T细胞免疫疗法作为一种创新的治疗手段,通过激活患者自身的免疫系统,实现精准的抗肿瘤作用,从而改善患者预后。随着多款T细胞免疫疗法在全球范围内获批上市,该疗法在侵袭性B细胞淋巴瘤领域的应用日益广泛,但关于其临床规范应用尚无相关共识。因此,中国临床肿瘤学会(CSCO)淋巴瘤专家委员会结合循证医学证据和临床应用经验,讨论制定了T细胞免疫疗法治疗侵袭性B细胞淋巴瘤中国专家共识,旨在为我国医师临床规范化用药提供指导和建议。
As an innovative treatment,T-cell immunotherapy can activate the patient's own immune system to achieve precise anti-tumor effects,and improve the prognosis of patients.With the worldwide approval of multiple T-cell immunotherapies,it has increasingly been applied in aggressive B-cell lymphoma treatment.However,there is currently no relevant consensus on its standardized clinical application.By referring to evidence-based medical evidence and clinical application experience,the Lymphoma Expert Committee of Chinese Society of Clinical Oncology(CSCO)discussed and formulated the Chinese expert consensus on T-cell immunotherapy in treatment of aggressive B-cell lymphoma,aiming to provide standardized medication guidance and suggestions for the Chinese clinicians.
作者
中国临床肿瘤学会(CSCO)淋巴瘤专家委员会
马军
朱军
白鸥
范磊
黄海雯
刘澎
梅恒
钱文斌
陶荣
王黎
谢彦
易树华
张会来
赵东陆
Lymphoma Expert Committee of Chinese Society of Clinical Oncology(CSCO);Ma Jun;Zhu Jun(不详;Harbin Institute of Hematology and Oncology,Harbin 150010,China;Department of Lymphatic Oncology,Peking University Cancer Hospital and Beijing Institute of Cancer Prevention and Treatment,Key Laboratory of Malignant Tumor Pathogenesis and Transformation Research,Ministry of Education,Beijing 100142,China)
出处
《白血病.淋巴瘤》
2025年第5期257-268,共12页
Journal of Leukemia & Lymphoma
